Invest in theFuture of Genomics
Join us in revolutionizing personalized medicine through AI-powered genetic analysis. A $217B+ market opportunity with exponential growth potential.
$217B+
Market Size
Global Precision Medicine Market by 2028
487%
Revenue Growth
Year-over-Year Growth Rate
127+
Global Reach
Countries across 6 continents
3.2M+
Tests Processed
Genetic tests completed annually
Compelling Growth Metrics
Strong fundamentals and market leadership position us for continued exponential growth
Market Size
The precision medicine market is experiencing unprecedented growth, driven by advances in AI and declining sequencing costs.
Revenue Growth
Consistent triple-digit growth driven by expanding test portfolio and global market penetration.
Customer Retention
Industry-leading retention demonstrates the value and reliability of our genetic testing platform.
Partner Network
Strategic partnerships with hospitals, clinics, and research institutions across 45+ countries.
72%
Gross Margin
+8%$125M
ARR
+156%8.5:1
LTV:CAC
+2.1135%
Net Revenue Retention
+15%Massive Addressable Market
The global precision medicine market is projected to reach $217.8 billion by 2028, with genomics testing representing $66.5B+ growing at 19.4% CAGR
Pharmacogenomics
Personalized medication optimization based on genetic profiles
Oncology Testing
Hereditary cancer risk assessment and early detection
Nutrigenomics
Diet and nutrition optimization through genetic insights
Carrier Screening
Reproductive health and family planning genetics
$66.5B+
Total Genomics Market by 2028
$15.8B
Pharmacogenomics
+13.2% CAGR
$28.4B
Oncology Testing
+15.7% CAGR
$12.6B
Nutrigenomics
+17.8% CAGR
$9.7B
Carrier Screening
+12.9% CAGR
Growth Timeline
From a bold idea in 2017 to a global genomics leader
Company Founded
Gene Matrix AI launched with a vision to democratize genetic testing through AI-powered analysis and precision medicine.
Company Founded
Gene Matrix AI launched with a vision to democratize genetic testing through AI-powered analysis and precision medicine.
CLIA & CE-IVD Certification
Achieved CLIA certification and CE-IVD Certified status, establishing our laboratory as a gold standard in clinical genetic testing.
CLIA & CE-IVD Certification
Achieved CLIA certification and CE-IVD Certified status, establishing our laboratory as a gold standard in clinical genetic testing.
First Product Launch
Released GeneCore comprehensive health panel, achieving a landmark 100,000 tests processed within the first year.
First Product Launch
Released GeneCore comprehensive health panel, achieving a landmark 100,000 tests processed within the first year.
Provider Network Expansion
Onboarded 500+ healthcare providers and clinic partners across North America, building a robust clinical distribution network.
Provider Network Expansion
Onboarded 500+ healthcare providers and clinic partners across North America, building a robust clinical distribution network.
Global Expansion
Expanded operations into Europe and the Middle East, partnering with 300+ healthcare facilities across 12 countries including the UK, Germany, UAE, and Canada.
Global Expansion
Expanded operations into Europe and the Middle East, partnering with 300+ healthcare facilities across 12 countries including the UK, Germany, UAE, and Canada.
AI Platform Launch
Launched our proprietary AI genomics engine delivering 99.9% accuracy, real-time variant interpretation, and personalized health insights at scale.
AI Platform Launch
Launched our proprietary AI genomics engine delivering 99.9% accuracy, real-time variant interpretation, and personalized health insights at scale.
Market Leadership
Reached 1M+ tests processed, recognized as a top-tier genomics platform with 850+ partner facilities across 12 countries.
Market Leadership
Reached 1M+ tests processed, recognized as a top-tier genomics platform with 850+ partner facilities across 12 countries.
Series A Funding — Coming Soon
Preparing to launch our Series A funding round to accelerate global expansion, deepen AI capabilities, and scale our provider network worldwide.
Series A Funding — Coming Soon
Preparing to launch our Series A funding round to accelerate global expansion, deepen AI capabilities, and scale our provider network worldwide.
World-Class Team
Industry veterans with proven track records in genomics, AI, and scaling healthcare companies
Tarek Younis
Chief Executive Officer
Tarek Younis is the visionary founder and CEO of Gene Matrix AI, leading the company's mission to revolutionize healthcare through AI-powered genetic diagnostics. With over 15 years of experience in healthcare technology and biotechnology.
Tarek Younis
Chief Executive Officer
Dr. James Chen
Chief Scientific Officer
Lammy Shaheen
Executive Director of Business & Operations
Saso Poposki
President of European Operations
Dr. Michael Okonkwo
Chief Medical Officer
Dr. Amara Nkosi
Director of African Markets
Advisory Board
Dr. Eric Lander
Former Science Advisor to President
Broad Institute
Mary Meeker
General Partner
Bond Capital
Dr. Francis Collins
Former NIH Director
NIH
John Doerr
Chairman
Kleiner Perkins
Partner With Innovation
Submit your inquiry to join our investment community and be part of the genomics revolution